The Abbott Laboratories (ABT) shares are trading at lower $101.53 and the avg recommendation for the stock is Moderate Buy. while the current analyst price target stands at $105.76.
To add more color to this target, the company’s high over the last year is $102.89 and the low is $61.61. Over the last 52 weeks, ABT is down -1.32% while the S&P 500 is down -0.36%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, ABT reported a profit of $4.07 billion. Abbott Laboratories also saw revenues increase to $7.33 billion. In addition, ABT has free cash flow of $1.03 billion as of 06-2020. The company’s EBITDA came in at $1.5 billion which compares well with its peers.
ABT booked profit margins of 11.70%, its Return on Equity (ROE) is 11.80%, and its Return on Assets is 5.40%. All told, it is clear that, ABT needs to be on your watchlist.
Find out when ABT reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. ABT has a short ratio of 1.64 and outstanding shares of 1.77B.
ABT has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 4.8 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at 1.73. Abbott Laboratories ABT also noted assets of $68.78 billion at the end of the last quarter. Investors should also keep an eye on sector updates as ABT has historically followed its peers on positive news.
All told, Abbott Laboratories ABT has strung together solid data and demonstrated underlying fundamentals. At its current valuation, ABT represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Abbott Laboratories ABT is now commanding a market cap of 182.98B and a float of 1.76B. ABT is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of ABT stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in ABT, either long or short, and we have not been compensated for this article.